Venrock healthcare survey shows pessimism on drug pricing

Skepticism remains high that the drug pricing debate will lead to action despite the FDA vowing to combat high drug prices. That was one of the findings in a survey of 300 healthcare experts conducted by the venture firm Venrock. A majority of those polled said that they believe there will still be more talk than action on prescription drug prices, with 19 percent believing that nothing will happen with prescription drug prices.

Among the other findings of the second annual survey: AI is overhyped, with only 7 percent anticipating success in AI in healthcare this year. In addition, 73 percent of respondents felt that the Amazon-Berkshire Hathaway-JPMorgan Chase partnership was going to face substantial challenges and take lots of time.

A PDF of the survey results are available at hcprognosis2018.venrock.com.

Photo of pills and capsules falling courtesy of Artfoliophoto/iStock/Getty Images.